Olema Pharmaceuticals (OLMA) Interest Expenses (2020 - 2026)

Olema Pharmaceuticals (OLMA) has 7 years of Interest Expenses data on file, last reported at $91.9 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 6861.44% year-over-year to $91.9 million in Q1 2026; TTM through Mar 2026 was $91.9 million, a 6861.44% increase from a year earlier, with the FY2025 full-year figure at $235.7 million, up 3034.19% from the prior year.
• Interest Expenses for Q1 2026 stood at $91.9 million, up from $312000.0 in the prior quarter.
• Over the last five years, Interest Expenses for OLMA reached as high as $91.9 million in Q1 2026 and fell as low as $263000.0 in Q4 2023.
• Historically, Interest Expenses has averaged $19.8 million across 5 years, with a median of $3.4 million in 2022.
• Across the five-year window, Interest Expenses tumbled 99.29% in 2025 and jumped 6861.44% in 2026, its largest moves.
• Year by year, Interest Expenses stood at $323000.0 in 2022, then decreased by 18.58% to $263000.0 in 2023, then grew by 16.35% to $306000.0 in 2024, then climbed by 1.96% to $312000.0 in 2025, then surged by 29352.24% to $91.9 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $91.9 million in Q1 2026, $312000.0 in Q3 2025, and $1.9 million in Q2 2025.